Accendra Health, Inc. is in the midst of a multiyear turnaround focusing on at-home medicine after selling its hospital supply unit and improving its balance sheet. The company recently refinanced its debt, reducing gross debt by about $100 million and extending maturities, which improves liquidity and the chances of successful long-term deleveraging. Management confirmed full-year guidance, but ongoing margin pressures and slow volume growth mean EBITDA is expected to be at the lower end of the forecast. Despite these challenges, the improved capital structure supports a Buy rating with a price target of around $7 by 2030, though the investment remains speculative due to high leverage.
The US Dollar and Brent crude oil prices have shown an unusual positive correlation of 0.55, the highest since 2005, coinciding with the Iran war's onset in March 2026. Typically, these move inversely because oil is priced in US Dollars, but geopolit...
Ray Dalio, founder of Bridgewater Associates, expressed concerns about the declining global influence of the United States amid China's growing economic power, now estimated at 60-70% of the US economy. After spending significant time in Asia, Dalio ...
Venture capitalist Chamath Palihapitiya predicts Taiwan will lose its critical strategic role in semiconductor supply within 18 months as the US rapidly expands its domestic chip manufacturing capabilities. He highlighted that US fabs are nearing the...
The cryptocurrency market dropped nearly $90 billion in value due to rising inflation data and reduced expectations for Federal Reserve interest rate cuts in 2026. Bitcoin fell below $79,000, briefly hitting $77,678, while Ethereum and XRP also decli...
Nvidia's stock is experiencing intense options trading and a potential short squeeze ahead of its earnings report scheduled for May 20. This heightened activity reflects strong market anticipation but may reset after the results and a drop in implied...
